Outcomes of Infants Who Failed to Extubate despite Systemic Corticosteroids
08 February 2017
13 June 2017
13 July 2017 (eFirst)
Objective The objective of this study was to assess the outcomes of preterm infants who failed to extubate following initial treatment with steroids.
Materials and Methods This is a retrospective cohort study of ventilator-dependent preterm infants treated with first course of systemic steroids to facilitate extubation. Outcomes of infants who successfully extubated were compared with infants who failed to extubate.
Results In this study, 74 infants (mean gestation 25.4 ± 1.4 weeks and mean birth weight 764 ± 163 g) met inclusion criteria. Of these, 41 (55%) were successfully extubated and 33 (45%) were not. Baseline demographics were similar between the two groups. The primary outcome of severe bronchopulmonary dysplasia (BPD) or death at 36 weeks was higher among infants who failed to extubate (94 vs. 63%, p = 0.002). Severe BPD remained significantly higher even after adjustment for potential confounders (odds ratio: 12.2, 95% confidence interval: 2.1–70.5, p = 0.005). Extubation failure was also associated with substantially higher rate of tracheostomy (32 vs. 5%, p = 0.003) and gastrostomy tube placement (61 vs. 22%, p = 0.001), as well as longer days of hospitalization (179 ± 72 vs. 129 ± 44 days, p = 0.001) and mechanical ventilation (112 ± 89 vs. 52 ± 42 days, p < 0.001).
Conclusion Failure to extubate after first course of systemic steroids for BPD is associated with poor prognostic implications.
- 1 Walsh MC, Morris BH, Wrage LA. , et al; National Institutes of Child Health and Human Development Neonatal Research Network. Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. J Pediatr 2005; 146 (06) 798-804
- 2 Gaillard EA, Cooke RW, Shaw NJ. Improved survival and neurodevelopmental outcome after prolonged ventilation in preterm neonates who have received antenatal steroids and surfactant. Arch Dis Child Fetal Neonatal Ed 2001; 84 (03) F194-F196
- 3 Thomas M, Greenough A, Morton M. Prolonged ventilation and intact survival in very low birth weight infants. Eur J Pediatr 2003; 162 (02) 65-67
- 4 Doyle LW, Ehrenkranz RA, Halliday HL. Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2014; (05) CD001145
- 5 Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. J Pediatr 2014; 165 (06) 1258-1260
- 6 Jobe AH. Postnatal corticosteroids for bronchopulmonary dysplasia. Clin Perinatol 2009; 36 (01) 177-188
- 7 Ohlsson A, Calvert SA, Hosking M, Shennan AT. Randomized controlled trial of dexamethasone treatment in very-low-birth-weight infants with ventilator-dependent chronic lung disease. Acta Paediatr 1992; 81 (10) 751-756
- 8 Rozycki HJ, Byron PR, Elliott GR, Carroll T, Gutcher GR. Randomized controlled trial of three different doses of aerosol beclomethasone versus systemic dexamethasone to promote extubation in ventilated premature infants. Pediatr Pulmonol 2003; 35 (05) 375-383
- 9 Walther FJ, Findlay RD, Durand M. Adrenal suppression and extubation rate after moderately early low-dose dexamethasone therapy in very preterm infants. Early Hum Dev 2003; 74 (01) 37-45
- 10 Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB. ; DART Study Investigators. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 2006; 117 (01) 75-83
- 11 Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 1989; 320 (23) 1505-1510
- 12 Rastogi A, Akintorin SM, Bez ML, Morales P, Pildes RS. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics 1996; 98 (2 Pt 1): 204-210
- 13 Garland JS, Alex CP, Pauly TH. , et al. A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Pediatrics 1999; 104 (1 Pt 1): 91-99
- 14 Truog WE, Nyp MF, Taylor J. , et al. Infants born at <29 weeks: pulmonary outcomes from a hybrid perinatal system. J Perinatol 2014; 34 (01) 59-63
- 15 Cuna A, Govindarajan S, Oschman A. , et al. A comparison of 7-day versus 10-day course of low-dose dexamethasone for chronically ventilated preterm infants. J Perinatol 2017; 37 (03) 301-305
- 16 Walsh MC, Yao Q, Gettner P. , et al; National Institute of Child Health and Human Development Neonatal Research Network. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics 2004; 114 (05) 1305-1311
- 17 Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr 2013; 13: 59
- 18 Kuschel C, Evans N, Lam A. Prediction of individual response to postnatal dexamethasone in ventilator dependent preterm infants. Arch Dis Child Fetal Neonatal Ed 1998; 78 (03) F199-F203
- 19 Kothadia JM, O'Shea TM, Auringer ST, Dillard RG. Response to dexamethasone in ventilated preterm infants: effect of radiographic subtype of chronic lung disease. Am J Perinatol 1996; 13 (06) 377-381
- 20 Kothadia JM, O'Shea TM, Roberts D, Auringer ST, Weaver III RG, Dillard RG. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants. Pediatrics 1999; 104 (1 Pt 1): 22-27
- 21 Kulkarni AP, Agarwal V. Extubation failure in intensive care unit: predictors and management. Indian J Crit Care Med 2008; 12 (01) 1-9
- 22 Ferguson KN, Roberts CT, Manley BJ, Davis PG. Interventions to improve rates of successful extubation in preterm infants: a systematic review and meta-analysis. JAMA Pediatr 2017; 171 (02) 165-174
- 23 Walsh MC, Yao Q, Horbar JD, Carpenter JH, Lee SK, Ohlsson A. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 2006; 118 (05) e1328-e1335
- 24 Watterberg KL. ; American Academy of Pediatrics. Committee on Fetus and Newborn. Policy statement--postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010; 126 (04) 800-808